Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prucalopride for refractory gastro-esophageal reflux disease with incomplete PPI response
2017-004175-31Phase 4Active
- Sponsor
- Targid
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in refractory gastroesophageal reflux disease (rGERD) comparing Prucalopride (Resolor) arm with Placebo arm (2 arms). Primary endpoint: Change in reflux parameters. Started Jan 2018; status: active.
02
Drugs
prucalopride
03
Conditions
refractory gastroesophageal reflux disease (rGERD)
Beyond the preview
Go deeper on 2017-004175-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004175-31.